A phase II study of thymoglobulin in patients with multiple myeloma who are candidates for allogeneic or autologous stem cell transplant
Latest Information Update: 07 Apr 2022
Price :
$35 *
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Nov 2011 Actual end date (June 2007) added as reported by ClinicalTrials.gov.
- 10 Jul 2007 Status changed from recruiting to completed.
- 15 Oct 2006 New trial record.